Mitogen-activated protein kinase pathway inhibitors: Inhibitors for diseases?

被引:0
|
作者
Wang X. [1 ,2 ]
Gong X.-W. [2 ]
Li Y.-H. [1 ]
Jiang Y. [2 ]
机构
[1] College of Life Science, Northeast Forestry University
[2] Key Laboratory of Functional Proteomics of Guangdong Province, Department of Pathophysiology, Southern Medical University
来源
Frontiers of Medicine in China | 2010年 / 4卷 / 1期
基金
中国国家自然科学基金;
关键词
Disease; Drug target; Inhibitor; Mitogen-activated protein kinase; Signal transduction;
D O I
10.1007/s11684-010-0010-0
中图分类号
学科分类号
摘要
Mitogen-activated protein kinase (MAPK) signaling pathway, one of the most important signaling pathways in eukaryotic organism, is involved in multiple cellular events such as cell growth, differentiation, and apoptosis. MAPK is of great importance to the normal function of organisms, while its dysfunction results in various diseases. So far, inhibitors specifically against each subfamilies of MAP kinase have been developed, while more endeavors are needed to discover the compounds selectively targeting a particular subfamily member. Most of the kinase inhibitors exert their functions in an ATP-competitive way or a non-ATP-competitive way. Further studies on the effective mechanism of the MAPK inhibitors and their therapeutic roles in the treatment of diseases are helpful for the illumination of MAP kinase function, the development of novel inhibitors, and the therapy of diseases caused by the dysfunction of the MAPK pathway. © 2010 Higher Education Press and Springer Berlin Heidelberg.
引用
收藏
页码:46 / 53
页数:7
相关论文
共 50 条
  • [1] Targeting the RAS pathway by mitogen-activated protein kinase inhibitors
    Kiessling, Michael K.
    Rogler, Gerhard
    [J]. SWISS MEDICAL WEEKLY, 2015, 145
  • [2] Novel mitogen-activated protein kinase kinase inhibitors
    Chapman, Mark S.
    Miner, Jeffrey N.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (02) : 209 - 220
  • [3] ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
    Goetz, Eva M.
    Ghandi, Mahmoud
    Treacy, Daniel J.
    Wagle, Nikhil
    Garraway, Levi A.
    [J]. CANCER RESEARCH, 2014, 74 (23) : 7079 - 7089
  • [4] Ocular Toxicity of Mitogen-Activated Protein Kinase Inhibitors
    Purbrick, Robert M. J.
    Osunkunle, Olaoluwakitan A.
    Talbot, Denis C.
    Downes, Susan M.
    [J]. JAMA ONCOLOGY, 2017, 3 (02) : 275 - 277
  • [5] Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways
    Malemud, Charles J.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2007, 7 (03) : 339 - 343
  • [6] Cardiac Effects of Mitogen-activated Protein Kinase Inhibitors in Children
    Su, Jennifer A.
    Robison, Nathan J.
    Malvar, Jemily
    Menteer, Jondavid
    [J]. CIRCULATION, 2019, 140
  • [7] Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) as Treatment for Inflammatory Diseases
    Abdel-Magid, Ahmed F.
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2024, 15 (09): : 1421 - 1423
  • [8] Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway
    Yu, CR
    Wang, SJ
    Dent, P
    Grant, S
    [J]. MOLECULAR PHARMACOLOGY, 2001, 60 (01) : 143 - 154
  • [9] New small-molecule inhibitors of mitogen-activated protein kinase kinase
    Spicer, Julie A.
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (07) : 801 - 817
  • [10] Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors
    Faghfuri, Elnaz
    Nikfar, Shekoufeh
    Niaz, Kamal
    Faramarzi, Mohammad Ali
    Abdollahi, Mohammad
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (03) : 317 - 330